Deterioration in asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down"

Journal of Asthma

Volumn 45, Issue 8, 2008, Pages 681-687

  Koenig, Steven M ^a   Ostrom, Nancy ^b   Pearlman, David ^c   Waitkus Edwards, Kelli ^d   Yancey, Steven ^d   Prillaman, Barbara A ^d   Dorinsky, Paul ^d  

^a UNIVERSITY OF VIRGINIA   (United States)

^b ALLERGY AND ASTHMA MEDICAL GROUP AND RESEARCH CENTER   (United States)

^c Respiratory Institute   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Fluticasone propionate; Montelukast; Salmeterol

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST; SALBUTAMOL; SALMETEROL XINAFOATE; TRIAMCINOLONE ACETONIDE;

ADULT; ARTICLE; ASTHMA; BACKACHE; CLINICAL FEATURE; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEADACHE; HUMAN; INFLAMMATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; RANDOMIZED CONTROLLED TRIAL; SMOOTH MUSCLE; THRUSH; UPPER RESPIRATORY TRACT INFECTION;

ACETATES; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY FLOW RATES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW RATE; QUESTIONNAIRES; QUINOLINES;

EID: 54949154566     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.1080/02770900802168695     Document Type: Article

References (16)

1. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma. Expert Panel Report 3. Bethesda, MD; National Institutes of Health, National Heart, Lung, and Blood Institute; 2007; NIH publication 08-4051.
2. Pauwels RA, Lofdahl C-G, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337:1405-1411.
3. Matz J, Emmett A, Rickard K, Kalberg, C. Addition of salmeterol to lowdose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107:783-789.
4. Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O'Byrne PM, Lofdahl CG, Pauwels RA, Ullman A. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160:594-599.
5. Taylor DR, Town GI, Herbison GP, Boothman-Burrell D, Flannery EM, Hancox B, Harre E, Laubscher K, Linscott V, Ramsay CM, Richards G. Asthma control during long term treatment with regular inhaled salbutamol and salmeterol. Thorax 1998; 53:744-752.
6. Busse W, Koenig SM, Oppenheimer J, Sahn SA, Yancey SW, Reilly D, Edwards LD, Dorinsky PM. Steroid-sparing effects of fluticasone propionate 100 mcg and salmeterol 50 mcg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 mcg administered twice daily. J Allergy Clin Immunol 2003; 111:57-65.
7. Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105:1108-1116.
8. Shapiro G, Lumry W, Wolfe J, Given J, White MV, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50μg and fluticasone propionate 250μg in the Diskus device for the treatment of asthma. Am J Respir Crit Care Med 2000; 161:527-534.
9. Aubier M, Pieters WR, Schlosser NJ, Steinmetz KO. Salmeterol/fluticasone propionate (50/50 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 1999; 93:876-884.
10. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-244.
11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129:15-26.
12. McIvor RA, Pizzichini C, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 1998; 158:924-930.
13. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, Kraft M, Fish JE, Peters SP, Craig T, Drazen JM, Ford JG, Israel E, Martin RJ, Mauger EA, Nachman SA, Spahn JD, Szefler SJ. Long-acting beta2-agonist monotherapy vs. continued therapy with inhaled corticosteroids in patients with persistent asthma. JAMA 2001; 285:2583-2593.
14. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, Seidenberg BC, Reiss TF. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 1999; 130:487-495.
15. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig J. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113:245-251.
16. Bateman ED, Britton M, Carrillo J, Almeida J, Wixon C. Salmeterol/Fluticasone Combination Inhaler: A New Effective and Well Tolerated Treatment for Asthma. Clin Drug Invest 1998; 16:193-201.